Sygnature Discovery, a provider of integrated drug discovery services, and Proteros, a biotechnology company in X-ray protein structure analysis, have entered a strategic alliance. Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects. This new alliance adds an integral component to Sygnature’s “federated” CRO model.

Dr. Simon Hirst, Sygnature’s CEO said, “With the addition of Proteros to the ‘federated’ CRO model, it enables Sygnature to offer its customers a world-class, fully-integrated drug discovery service where novel compounds can be designed, synthesized and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models.”